- Home
- KLRS vs AKA Comparison
KLRS vs AKA Comparison
Compare KLRS & AKA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | KLRS | AKA |
|---|---|---|
| Founded | 2019 | 2018 |
| Country | United States | United States |
| Employees | 20 | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Catalog/Specialty Distribution |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 117.1M | 105.4M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | KLRS | AKA |
|---|---|---|
| Price | $4.07 | $10.71 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 3 |
| Target Price | $19.00 | ★ $24.33 |
| AVG Volume (30 Days) | ★ 74.4K | 4.5K |
| Earning Date | 05-13-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $600,208,000.00 |
| Revenue This Year | N/A | $6.14 |
| Revenue Next Year | N/A | $4.89 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 4.44 |
| 52 Week Low | $2.14 | $8.42 |
| 52 Week High | $11.88 | $16.38 |
Technical Indicators
Market Signals| Indicator | KLRS | AKA |
|---|---|---|
| Relative Strength Index (RSI) | 35.60 | 69.20 |
| Support Level | N/A | $10.40 |
| Resistance Level | $5.48 | $11.42 |
| Average True Range (ATR) | 0.31 | 0.52 |
| MACD | 0.01 | 0.29 |
| Stochastic Oscillator | 17.22 | 86.60 |
Price Performance
Historical ComparisonAbout KLRS Kalaris Therapeutics Inc.
Kalaris Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for prevalent retinal diseases. The company is developing TH103, a novel, clinical-stage anti-vascular endothelial growth factor VEGF drug, engineered to potentially provide longer-lasting and increased anti-VEGF activity in patients with exudative and neovascular retinal diseases. TH103 is a fully humanized recombinant fusion protein, functioning as a decoy receptor (a VEGF trap), leveraging salient molecular properties of the human body's native, highest affinity VEGF receptor 1.
About AKA a.k.a. Brands Holding Corp.
a.k.a. Brands Holding Corp is a portfolio of fashion brands, including Princess Polly, Culture Kings, Petal & Pup, and mnml. Through these brands, the company reaches next-generation consumers who seek fashion inspiration on social media and mainly shop online. The portfolio consists of two women's brands, Princess Polly and Petal & Pup, and two streetwear brands, Culture Kings and mnml. The company generates the majority of its revenue from the United States.